Skip to main content
. 2023 Jul 26;15:164. doi: 10.1186/s13098-023-01118-6

Fig. 5.

Fig. 5

Subgroup analysis: GLP-1 receptor agonists and Respiratory disease. CVOT: Cardiovascular Outcomes Trial